Cited by 455Protein purification and stabilityProtein Structure and DynamicsHeat shock proteins research

The DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.

Therapeutic protein aggregation: mechanisms, design, and control

Open access

Roberts, Christopher J.·2014·Trends in Biotechnology

DOI 10.1016/j.tibtech.2014.05.005PMC PMC4146573

Open this paper in CoChat — free account

Abstract

Although it is well known that proteins are only marginally stable in their folded states, it is often less well appreciated that most proteins are inherently aggregation-prone in their unfolded or partially unfolded states, and the resulting aggregates can be extremely stable and long-lived. For therapeutic proteins, aggregates are a significant risk factor for deleterious immune responses in patients, and can form via a variety of mechanisms. Controlling aggregation using a mechanistic approach may allow improved design of therapeutic protein stability, as a complement to existing design strategies that target desired protein structures and function. Recent results highlight the importance of balancing protein environment with the inherent aggregation propensities of polypeptide chains.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.tibtech.2014.05.005

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Intermolecular and Surface Forces
(2011) · Elsevier eBooks · doi:10.1016/b978-0-12-391927-4.10024-6 · Cited by 17,242
Protein Folding
Creighton, T. E. (1992) · Cited by 1,583
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,179
Rationalization of the effects of mutations on peptide andprotein aggregation rates
Chiti, F., Stefani, M., Taddei, N., Ramponi, G., & Dobson, C. M. (2003) · Nature · doi:10.1038/nature01891 · Cited by 1,072
Protein aggregation and its inhibition in biopharmaceutics
Wang, W. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.11.014 · Cited by 1,023
Antibody Structure, Instability, and Formulation
Wang, W., Singh, S. K., Zeng, D. L., King, K., & Nema, S. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20727 · Cited by 948
The immunogenicity of humanized and fully human antibodies
Harding, F., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010) · mAbs · doi:10.4161/mabs.2.3.11641 · Cited by 743
Protein aggregation kinetics, mechanism, and curve-fitting: A review of the literature
Morris, A. M., Watzky, M. A., & Finke, R. G. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2008.10.016 · Cited by 693
Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity
Boder, E. T., Midelfort, K. S., & Wittrup, K. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.170297297 · Cited by 673

Show all 102 references

Sorted by citations

Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Protein aggregation and its impact on product quality
Roberts, C. J. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.08.001 · Cited by 318
Self-citation
Considerations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 328
Protein aggregation – Mechanisms, detection, and control
Wang, W., & Roberts, C. J. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.043 · Cited by 328
Self-citation
Protein aggregation, particle formation, characterization & rheology
Amin, S., Barnett, G. V., Pathak, J. A., Roberts, C. J., & Sarangapani, P. S. (2014) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2014.10.002 · Cited by 283
Self-citation
Ion Mobility Mass Spectrometry (IM-MS) for Structural Biology: Insights Gained by Measuring Mass, Charge, and Collision Cross Section
Christofi, E., & Barran, P. E. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00600 · Cited by 248
A comprehensive comparison between camelid nanobodies and single chain variable fragments
Asaadi, Y., Jouneghani, F. F., Janani, S., & Rahbarizadeh, F. (2021) · Biomarker Research · doi:10.1186/s40364-021-00332-6 · Cited by 221
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Review of the current state of protein aggregation inhibition from a materials chemistry perspective: special focus on polymeric materials
Rajan, R., Ahmed, S. G., Sharma, N., Kumar, N., Debas, A., & Matsumura, K. (2021) · Materials Advances · doi:10.1039/d0ma00760a · Cited by 202
Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment
Kintzing, J. R., Interrante, M. V. F., & Cochran, J. R. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.005 · Cited by 199
Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems
Shi, M., & McHugh, K. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114904 · Cited by 194
Analytical methods for process and product characterization of recombinant adeno-associated virus-based gene therapies
Gimpel, A. L., Katsikis, G., Sha, S., Maloney, A. J., Hong, M. S., Nguyen, T. N. T., Wolfrum, J., Springs, S. L., Sinskey, A. J., Manalis, S. R., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.010 · Cited by 185
Protein aggregation and immunogenicity of biotherapeutics
Pham, N. B., & Meng, W. S. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119523 · Cited by 185
The structural basis of nanobody unfolding reversibility and thermoresistance
Kunz, P., Zinner, K., Mücke, N., Bartoschik, T., Muyldermans, S., & Hoheisel, J. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-26338-z · Cited by 184
Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins
Turner, M. R., & Balu‐Iyer, S. V. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.01.007 · Cited by 178
Engineering antibody therapeutics
Chiu, M. L., & Gilliland, G. L. (2016) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2016.07.012 · Cited by 175
Stabilization challenges and aggregation in protein-based therapeutics in the pharmaceutical industry
Rahban, M., Ahmad, F., Piatyszek, M. A., Haertlé, T., Saso, L., & Saboury, A. A. (2023) · RSC Advances · doi:10.1039/d3ra06476j · Cited by 166
The fickle CHO: a review of the causes, implications, and potential alleviation of the CHO cell line instability problem
Dahodwala, H., & Lee, K. H. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.011 · Cited by 160
Overview of Antibody Drug Delivery
Awwad, S., & Angkawinitwong, U. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030083 · Cited by 159
Antibody Aggregation: Insights from Sequence and Structure
Li, W., Prabakaran, P., Chen, W., Zhu, Z., Feng, Y., & Dimitrov, D. S. (2016) · Antibodies · doi:10.3390/antib5030019 · Cited by 156
Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation
Narayanan, H., Dingfelder, F., Butté, A., Lorenzen, N., Sokolov, M., & Arosio, P. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.12.004 · Cited by 151
Third generation antibody discovery methods: in silico rational design
Sormanni, P., Aprile, F. A., & Vendruscolo, M. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00523k · Cited by 143
Rapid and accurate in silico solubility screening of a monoclonal antibody library
Sormanni, P., Amery, L., Ekizoglou, S., Vendruscolo, M., & Popovic, B. (2017) · Scientific Reports · doi:10.1038/s41598-017-07800-w · Cited by 136
Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
Dobson, C., Devine, P. W. A., Phillips, J. J., Higazi, D. R., Lloyd, C., Popovic, B., Arnold, J., Buchanan, A. G., Lewis, A. R., Goodman, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38644 · Cited by 117
Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment
Chu, C., Su, M., Zhu, J. X., Li, D., Cheng, H., Chen, X. S., & Liu, G. (2019) · Theranostics · doi:10.7150/thno.33539 · Cited by 118
The Protein Folding Problem: The Role of Theory
Nassar, R., Dignon, G. L., Razban, R. M., & Dill, K. A. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167126 · Cited by 111
Machine learning prediction of antibody aggregation and viscosity for high concentration formulation development of protein therapeutics
Lai, P.-K., Gallegos, A., Mody, N., Sathish, H. A., & Trout, B. L. (2022) · mAbs · doi:10.1080/19420862.2022.2026208 · Cited by 103
In vitro and in silico assessment of the developability of a designed monoclonal antibody library
Wolf Pérez, A.-M., Sormanni, P., Andersen, J. S., Sakhnini, L. I., Rodriguez-Leon, I., Bjelke, J. R., Gajhede, A. J., De Maria, L., Otzen, D. E., Vendruscolo, M., et al. (2019) · mAbs · doi:10.1080/19420862.2018.1556082 · Cited by 97
Towards a Digital Bioprocess Replica: Computational Approaches in Biopharmaceutical Development and Manufacturing
Smiatek, J., Jung, A., & Bluhmki, E. (2020) · Trends in biotechnology · doi:10.1016/j.tibtech.2020.05.008 · Cited by 98
Coarse-Grained Antibody Models for “Weak” Protein–Protein Interactions from Low to High Concentrations
Calero‐Rubio, C., Saluja, A., & Roberts, C. J. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b04907 · Cited by 95
Self-citation
High concentration formulation developability approaches and considerations
Zarzar, J., Khan, T. A., Bhagawati, M., Weiche, B., Sydow-Andersen, J., & Sreedhara, A. (2023) · mAbs · doi:10.1080/19420862.2023.2211185 · Cited by 94
Fluorogenic Detection and Characterization of Proteins by Aggregation‐Induced Emission Methods
Xie, S., Wong, A. Y. H., Chen, S., & Tang, B. Z. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201805297 · Cited by 88
SOLart: a structure-based method to predict protein solubility and aggregation
Hou, Q., Kwasigroch, J. M., Rooman, M., & Pucci, F. (2020) · Bioinformatics · doi:10.1093/bioinformatics/btz773 · Cited by 86
Relating Protein–Protein Interactions and Aggregation Rates From Low to High Concentrations
Ghosh, R., Calero‐Rubio, C., Saluja, A., & Roberts, C. J. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.01.004 · Cited by 85
Self-citation
The second virial coefficient as a predictor of protein aggregation propensity: A self-interaction chromatography study
Quigley, A., & Williams, D. R. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.07.025 · Cited by 82
Molecular and functional analysis of monoclonal antibodies in support of biologics development
Wang, X., An, Z., Luo, W., Xia, N., & Zhao, Q. (2017) · Protein & Cell · doi:10.1007/s13238-017-0447-x · Cited by 82
Thermodynamic phase diagram of amyloid-β (16–22) peptide
Wang, Y., Bunce, S. J., Radford, S. E., Wilson, A. J., Auer, S., & Hall, C. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819592116 · Cited by 82
On the Applicability of Force Fields To Study the Aggregation of Amyloidogenic Peptides Using Molecular Dynamics Simulations
Carballo‐Pacheco, M., Ismail, A. E., & Strodel, B. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00579 · Cited by 82
Driving Forces for Nonnative Protein Aggregation and Approaches to Predict Aggregation-Prone Regions
Meric, G., Robinson, A. S., & Roberts, C. J. (2017) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060816-101404 · Cited by 78
Self-citation
Toward Drug-Like Multispecific Antibodies by Design
Sawant, M. S., Streu, C. N., Wu, L., & Tessier, P. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207496 · Cited by 77
Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers
Collins, D. S., Kourtis, L. C., Thyagarajapuram, N. R., Sirkar, R., Kapur, S., Harrison, M. W., Bryan, D. J., Jones, G. B., & Wright, J. M. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2229-9 · Cited by 75
Computational prediction of protein aggregation: Advances in proteomics, conformation-specific algorithms and biotechnological applications
Santos, J., Pujols, J., Pallarès, I., Iglesias, V., & Ventura, S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.05.026 · Cited by 74
Stability testing in monoclonal antibodies
Kaur, H. (2021) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1874281 · Cited by 76
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Heterogeneous anomalous transport in cellular and molecular biology
Waigh, T. A., & Nickolay Korabel, A. (2023) · Reports on Progress in Physics · doi:10.1088/1361-6633/ad058f · Cited by 68
Boosting antibody developability through rational sequence optimization
Seeliger, D., Schulz, P., Litzenburger, T., Spitz, J., Hoerer, S., Blech, M., Enenkel, B., Studts, J., Garidel, P., & Karow‐Zwick, A. R. (2015) · mAbs · doi:10.1080/19420862.2015.1017695 · Cited by 67
Connecting high-temperature and low-temperature protein stability and aggregation
Rosa, M., Roberts, C. J., & Rodrigues, M. Â. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176748 · Cited by 66
Self-citation
Stress Factors in mAb Drug Substance Production Processes: Critical Assessment of Impact on Product Quality and Control Strategy
Das, T. K., Narhi, L. O., Sreedhara, A., Menzen, T., Grapentin, C., Chou, D. K., Antochshuk, V., & Filipe, V. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.09.023 · Cited by 72
Non-polyphenolic natural inhibitors of amyloid aggregation
Ma, L., Yang, C., Zheng, J., Chen, Y., Xiao, Y., & Huang, K. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112197 · Cited by 66
Insights into protein misfolding and aggregation enabled by solid-state NMR spectroscopy
van der Wel, P. C. A. (2017) · Solid State Nuclear Magnetic Resonance · doi:10.1016/j.ssnmr.2017.10.001 · Cited by 64
Studying Excipient Modulated Physical Stability and Viscosity of Monoclonal Antibody Formulations Using Small-Angle Scattering
Xu, A. Y., Castellanos, M. M., Mattison, K. W., Krueger, S., & Curtis, J. E. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00687 · Cited by 63
Emerging Challenges and Innovations in Surfactant-mediated Stabilization of Biologic Formulations
Katz, J. S., Chou, D. K., Christian, T. R., Das, T. K., Patel, M., Singh, S. N., & Wen, Y. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.12.002 · Cited by 64
Aggregation and Its Influence on the Immunomodulatory Activity of Synthetic Innate Defense Regulator Peptides
Haney, E. F., Wu, B. C., Lee, K., Hilchie, A. L., & Hancock, R. E. W. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.07.010 · Cited by 65
Exploiting sequence and stability information for directing nanobody stability engineering
Kunz, P., Flock, T., Soler, N., Zaiß, M., Vincke, C., Sterckx, Y. G. ‐., Kastelic, D., Muyldermans, S., & Hoheisel, J. D. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.06.014 · Cited by 61
Practical guide to characterize biomolecule adsorption on solid surfaces (Review)
Migliorini, E., Weidenhaupt, M., & Picart, C. (2018) · Biointerphases · doi:10.1116/1.5045122 · Cited by 68
Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188
Grapentin, C., Müller, C., Kishore, R. S. K., Adler, M., Bialy, I. E., Frieß, W., Huwyler, J., & Khan, T. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.03.010 · Cited by 64
Protein aggregation and mitigation strategy in low pH viral inactivation for monoclonal antibody purification
Jin, W., Xing, Z., Song, Y., Huang, C., Xu, X., Ghose, S., & Li, Z. J. (2019) · mAbs · doi:10.1080/19420862.2019.1658493 · Cited by 61
pH-Dependent Aggregation in Intrinsically Disordered Proteins Is Determined by Charge and Lipophilicity
Santos, J., Iglesias, V., Santos-Suárez, J., Mangiagalli, M., Brocca, S., Pallarès, I., & Ventura, S. (2020) · Cells · doi:10.3390/cells9010145 · Cited by 59
Engaging with Raman Spectroscopy to Investigate Antibody Aggregation
Ettah, I., & Ashton, L. (2018) · Antibodies · doi:10.3390/antib7030024 · Cited by 58
Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization
Wälchli, R., Ressurreição, M., Vogg, S., Feidl, F., Angelo, J., Xu, X., Ghose, S., Li, Z. J., LeSaout, X., Souquet, J., et al. (2019) · Biotechnology and Bioengineering · doi:10.1002/bit.27237 · Cited by 57
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study
Joshi, S., & Rathore, A. S. (2020) · BioDrugs · doi:10.1007/s40259-020-00404-3 · Cited by 56
Control of viscosity in biopharmaceutical protein formulations
Zidar, M., Rozman, P., Parkel, K. B., & Ravnik, M. (2020) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.06.105 · Cited by 56
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 63
Toward Biotherapeutic Product Real‐Time Quality Monitoring
Guerra, A., von Stosch, M., & Glassey, J. (2019) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2018.1524362 · Cited by 58
Injectables and Depots to Prolong Drug Action of Proteins and Peptides
Ibeanu, N., Egbu, R., Onyekuru, L., Javaheri, H., Khaw, P. T., Williams, G. R., Brocchini, S., & Awwad, S. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100999 · Cited by 56
Bioengineering of nano metal-organic frameworks for cancer immunotherapy
Chong, G., Zang, J., Han, Y., Su, R., Weeranoppanant, N., Dong, H., & Li, Y. (2020) · Nano Research · doi:10.1007/s12274-020-3179-9 · Cited by 54
A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics
Zapadka, K. L., Becher, F. J., Uddin, S., Varley, P., Bishop, S., dos Santos, A. L. G., & Jackson, S. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b05025 · Cited by 55
Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility
Gil-García, M., Bañó‐Polo, M., Varejão, N., Jamroz, M., Kuriata, A., Díaz-Caballero, M., Lascorz, J., Morel, B., Navarro, S., Reverter, D., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00341 · Cited by 56
Unusual Aggregates Formed by the Self-Assembly of Proline, Hydroxyproline, and Lysine
Koshti, B., Kshtriya, V., Singh, R. S., Walia, S., Bhatia, D. D., Joshi, K. B., & Gour, N. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00427 · Cited by 54
Catalytic bioscavengers as countermeasures against organophosphate nerve agents
Goldsmith, M., & Ashani, Y. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.07.006 · Cited by 53
Accelerated Aggregation Studies of Monoclonal Antibodies: Considerations for Storage Stability
Wälchli, R., Vermeire, P., Massant, J., & Arosio, P. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.048 · Cited by 54
Pulsed Electric Field-Induced Modification of Proteins: A Comprehensive Review
Shams, R., Manzoor, S., Shabir, I., Dar, A. H., Dash, K. K., Srivastava, S., Pandey, V. K., Bashir, I., & Khan, S. A. (2023) · Food and Bioprocess Technology · doi:10.1007/s11947-023-03117-x · Cited by 52
Characterization of mAb dimers reveals predominant dimer forms common in therapeutic mAbs
Plath, F., Ringler, P., Graff-Meyer, A., Stahlberg, H., Lauer, M. E., Rufer, A. C., Graewert, M. A., Svergun, D. I., Gellermann, G. P., Finkler, C., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1168960 · Cited by 51
Evaluation of in vitro Assays to Assess the Modulation of Dendritic Cells Functions by Therapeutic Antibodies and Aggregates
Morgan, H., Tseng, S.-Y., Gallais, Y., Leineweber, M., Buchmann, P., Riccardi, S., Nabhan, M., Lo, J., Gani, Z., Szely, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00601 · Cited by 56
Influence and effect of osmolytes in biopharmaceutical formulations
Wlodarczyk, S. R., Custodio, D. F., Pessoa, A., & Monteiro, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.07.019 · Cited by 50
Accelerating therapeutic protein design with computational approaches toward the clinical stage
Chen, Z., Wang, X., Chen, X., Huang, J., Wang, C., Wang, J., & Wang, Z. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.04.027 · Cited by 49
Isothermal chemical denaturation as a complementary tool to overcome limitations of thermal differential scanning fluorimetry in predicting physical stability of protein formulations
Svilenov, H. L., Markoja, U., & Winter, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.004 · Cited by 49
Coaggregation of κ‐Casein and β‐Lactoglobulin Produces Morphologically Distinct Amyloid Fibrils
Raynes, J. K., Day, L., Crepin, P., Horrocks, M. H., & Carver, J. A. (2017) · Small · doi:10.1002/smll.201603591 · Cited by 47
Preferential interactions of trehalose, L-arginine.HCl and sodium chloride with therapeutically relevant IgG1 monoclonal antibodies
Sudrik, C., Cloutier, T. K., Pham, P., Samra, H. S., & Trout, B. L. (2017) · mAbs · doi:10.1080/19420862.2017.1358328 · Cited by 46
Characterisation of protein aggregation with the Smoluchowski coagulation approach for use in biopharmaceuticals
Zidar, M., Kuzman, D., & Ravnik, M. (2018) · Soft Matter · doi:10.1039/c8sm00919h · Cited by 43
Protein–Protein Interactions of Highly Concentrated Monoclonal Antibody Solutions via Static Light Scattering and Influence on the Viscosity
Hung, J., Dear, B. J., Karouta, C. A., Chowdhury, A. A., Godfrin, P. D., Bollinger, J. A., Nieto, M. P., Wilks, L. R., Shay, T. Y., Ramachandran, K., et al. (2019) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.8b09527 · Cited by 45
CPAD 2.0: a repository of curated experimental data on aggregating proteins and peptides
Rawat, P., Prabakaran, R., Sakthivel, R., Thangakani, A. M., Kumar, S., & Gromiha, M. M. (2020) · Amyloid · doi:10.1080/13506129.2020.1715363 · Cited by 46
Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods
Pérez, A.-M. W., Lorenzen, N., Vendruscolo, M., & Sormanni, P. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1450-1_4 · Cited by 43
Multi‐omics profiling of a CHO cell culture system unravels the effect of culture pH on cell growth, antibody titer, and product quality
Lee, A. P., Kok, Y. J., Lakshmanan, M., Leong, D., Zheng, L., Lim, H. L., Chen, S., Mak, S. Y., Ang, K. S., Templeton, N., et al. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27899 · Cited by 40
Using protein engineering to understand and modulate aggregation
Ebo, J. S., Guthertz, N., Radford, S. E., & Brockwell, D. J. (2020) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.01.005 · Cited by 44
Functional Characterization of Pembrolizumab Produced in Nicotiana benthamiana Using a Rapid Transient Expression System
Phakham, T., Bulaon, C. J. I., Khorattanakulchai, N., Shanmugaraj, B., Buranapraditkun, S., Boonkrai, C., Sooksai, S., Hirankarn, N., Abe, Y., Strasser, R., et al. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.736299 · Cited by 43
Computational models for studying physical instabilities in high concentration biotherapeutic formulations
Blanco, M. A. (2022) · mAbs · doi:10.1080/19420862.2022.2044744 · Cited by 43
Understanding and controlling the molecular mechanisms of protein aggregation in mAb therapeutics
Pang, K. T., Yang, Y., Zhang, W., Ho, Y. S., Sormanni, P., Michaels, T. C. T., Walsh, I., & Chia, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108192 · Cited by 42
New and Evolving Techniques for the Characterization of Peptide Therapeutics
D’Addio, S. M., Bothe, J. R., Neri, C., Walsh, P. L., Zhang, J., Pierson, E. E., Mao, Y. J., Gindy, M. E., Leone, A. M., & Templeton, A. C. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2016.06.011 · Cited by 41
HP-β-CD for the formulation of IgG and Ig-based biotherapeutics
Wu, H. H., Garidel, P., & Blech, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120531 · Cited by 42
Stability of Protein Pharmaceuticals: Recent Advances
Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., et al. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03726-x · Cited by 45
Computational Characterization of Antibody–Excipient Interactions for Rational Excipient Selection Using the Site Identification by Ligand Competitive Saturation-Biologics Approach
Jo, S., Xu, A. Y., Curtis, J. E., Somani, S., & MacKerell, A. D. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00775 · Cited by 40
Rapid, quantitative determination of aggregation and particle formation for antibody drug conjugate therapeutics with label-free Raman spectroscopy
Zhang, C., Springall, J. S., Wang, X., & Barman, I. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.07.007 · Cited by 40
Pre-formulation and delivery strategies for the development of bacteriocins as next generation antibiotics
Flynn, J., Ryan, A., & Hudson, S. P. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.05.015 · Cited by 41
Protein aggregation and crystallization with ionic liquids: Insights into the influence of solvent properties
Han, Q., Brown, S. J., Drummond, C. J., & Greaves, T. L. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2021.10.087 · Cited by 41
Stability of Proteins in Carbohydrates and Other Additives during Freezing: The Human Growth Hormone as a Case Study
Arsiccio, A., & Pisano, R. (2017) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b05541 · Cited by 39
High Throughput Differential Scanning Fluorimetry (DSF) Formulation Screening with Complementary Dyes to Assess Protein Unfolding and Aggregation in Presence of Surfactants
McClure, S. M., Ahl, P. L., & Blue, J. T. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2361-1 · Cited by 39
Capillary zone electrophoresis-native mass spectrometry for the quality control of intact therapeutic monoclonal antibodies
Le-Minh, V., Tran, N. T., Makky, A., Rosilio, V., Taverna, M., & Smadja, C. (2019) · Journal of Chromatography A · doi:10.1016/j.chroma.2019.05.050 · Cited by 41
An in vivo platform to select and evolve aggregation-resistant proteins
Ebo, J. S., Saunders, J. C., Devine, P. W. A., Gordon, A., Warwick, A. S., Schiffrin, B., Chin, S. E., England, E., Button, J. D., Lloyd, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15667-1 · Cited by 34
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties
Svilenov, H. L., Arosio, P., Menzen, T., Tessier, P. M., & Sormanni, P. (2023) · mAbs · doi:10.1080/19420862.2022.2164459 · Cited by 40

Authors: Roberts, C. J.
Affiliations: University of Delaware (US)
Corresponding author: Roberts, Christopher J.
ORCID: Roberts, Christopher J.
Venue: Trends in Biotechnology
Publisher: Elsevier BV
Published: 2014-07
Volume: 32
Issue: 7
Pages: 372-380
ISSN: 0167-7799 (ISSN-L)
DOI: 10.1016/j.tibtech.2014.05.005
PMC: PMC4146573
OpenAlex: W1972260684
Cited by: 455
References: 102
Citations by year: 2026: 46 · 2025: 35 · 2024: 39 · 2023: 41 · 2022: 38 · 2021: 48 · 2020: 53 · 2019: 58 · 2018: 46 · 2017: 26 · 2016: 16 · 2015: 7 · 2014: 2
FWCI: 1.60
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Trends in biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Science Foundation
Foundation for the National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering (R01EB006006)
National Center for Research Resources (P20RR015588)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: protein stability, aggregation-prone proteins, partially unfolded state, aggregation control, protein design, protein environment
MeSH terms: Biopharmaceutics, Biotechnology, Humans, Models, Molecular, Protein Conformation, Proteins, Protein Folding, Protein Stability, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic protein aggregation: mechanisms, design, and control

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks